Navigation Links
Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452
Date:5/26/2009

king statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with Amgen's products after they are on the market. Amgen's business may be impacted by government investigations, litigation and products liability claims. Amgen depends on third parties for a significant portion of its manufacturing capacity for the supply of certain of its current and future products and limits on supply may constrain sales of certain of its current products and product candidate development.

In addition, sales of Amgen's products are affected by the reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected b
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amgen Announces Voting Results Of Annual Meeting Of Stockholders
2. Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
3. Preclinical Data From Amgens Oncology Pipeline to be Presented at AACR
4. Amgen to Present at the Cowen and Company Annual Healthcare Conference
5. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
6. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
7. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
8. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
9. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
10. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
11. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... , Sept. 29, 2014  Atlas Venture, an early ... and technology innovation, today announced that Jason Rhodes ... EPZM ), is joining the firm,s life ... 2014. At Atlas, Rhodes will work closely ... He brings an accomplished record in company creation, deal ...
(Date:9/29/2014)... , September 29, 2014 ... greater competition to transform network connectivity as customers ... ProLabs , the leading independent ... today the findings of their survey conducted at ... with top optical communications professionals from across the ...
(Date:9/29/2014)... 2014 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that the U.S. ... Orphan Drug Designations for the Company,s lead drug ... small cell lung cancer and ovarian cancer.  Aldoxorubicin ... agent, doxorubicin. "The FDA,s decision to ...
(Date:9/28/2014)... Modality Solutions, a ... for highly regulated industries, is pleased to announce ... Advantage Transport Simulation Laboratoryâ„¢ software at the 12th ... Global Forum in Boston, September 29 through October ... lab software on October 2, day two of ...
Breaking Biology Technology:Atlas Venture Names Jason Rhodes, Veteran Investor and President and CFO of Epizyme, As Partner on Life Sciences Investing Team 2End of an Era: OEM Dominance - Could it be a Thing of the Past? 2CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 2CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 3CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 4CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 5Consulting Engineer Brian Brazill to Demonstrate Modality Solutions Advantage Transport Simulation Laboratory Software at 12th Annual Cold Chain Global Forum 2Consulting Engineer Brian Brazill to Demonstrate Modality Solutions Advantage Transport Simulation Laboratory Software at 12th Annual Cold Chain Global Forum 3
... , QIAshredder spin columns are designed for simple and rapid homogenization , of cell and ... , , Format: , ... , , Sample source: ... plant cell or tissue lysates, white blood cell lysates, , ...
... , , , , This ... human cancer-related genes for functional genomics research using , RNAi. ... , , , , ... cancer researchers (see table below for a list of genes). Every siRNA has , ...
... Competent Cells for added , convenience, , , , , , , ... Included , Concentration , , , ... , , , ... 50 ng/l, , , Ligation Master ...
Cached Biology Technology:QIAshredder Homogenizer 2Cancer siRNA Oligo Set Version 1.0 2Cancer siRNA Oligo Set Version 1.0 3Cancer siRNA Oligo Set Version 1.0 4
(Date:9/29/2014)... popular culture, mathematics is often deemed inaccessible or esoteric. ... more important role in our daily lives and a ... ideas often behind the scenes. , UC Santa ... Mathematics and an assistant professor of mechanical engineering, often ... of his recent research published in the Proceedings ...
(Date:9/29/2014)... that a combination of a real-time feedback system together ... residence resulted in a reduction of 37% in energy ... 1360.49 kWh, which is equivalent to a reduction of ... , In contrast, another eight halls, exposed only ... resulted in saw a 3.5% reduction in energy consumption. ...
(Date:9/29/2014)... not normally considered capable of doing anything on their ... move through water. In the future, such moving droplets ... your own to be self-moving is a ... entities can be self-moving, report researchers from University of ... Czech Republic. , The researchers have made alcohol droplets ...
Breaking Biology News(10 mins):At the interface of math and science 2At the interface of math and science 3At the interface of math and science 4Scientists make droplets move on their own 2
... Dr. Zhihong Chen and colleagues from Chengde Medical ... Akt signaling, decrease heme oxygenase-1 expression in the ... of hippocampal neurons in diabetic rats, thus protecting ... the growth hormone/insulin-like growth factor 1 axis undergoes ...
... taken part in an international study which has discovered a ... of a region. And the secret lies in crushed ... been spent by researchers gathering, classifying and recording insects and ... region. Any changes to the biodiversity of that area could ...
... Control, Automation and Electrical Systems , a new journal in ... as Controle and Automao , the new journal will ... available on Springer,s online platform, SpringerLink . ... covers industrial automation, addressing such topics as circuits and systems; ...
Cached Biology News:Insect 'soup' serving up rapid biodiversity monitoring 2Journal of Control, Automation and Electrical Systems now published by Springer 2
Taq DNA polymerase, 10,000U...
... - 5 units/µL ,• High specific activity ... Leaves an 'A' overhang ,• Processes ... very high activity in primer extension and ... quality of the enzyme, each lot has ...
... a versatile and easy-to use enzyme, with ... Taq DNA Polymerase is prepared from a ... the DNA polymerase I gene from Thermococcus ... 5'-3' DNA polymerase activity. Its inherent 3'-5' ...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
Biology Products: